Investing in promising science
As a charity, we want to ensure that promising science is developed and can make a difference to patients’ lives. To achieve this we have invested heavily in our drug discovery and diagnostics development capabilities.
Our work on drug discovery projects centres on early-stage academic research for conditions where there is a clear need for new treatments. We bring a 25-year track record and a highly experienced team of experts who can work with you to help develop your drug target and get it into the clinic faster.
There are three main areas in which we work.
Our biology team supports projects that aim to generate small molecule drugs rather than therapeutic antibodies. Our biologists work closely with our chemistry department. Their work is divided into two sections: assay development and screening, and compound profiling and cellular pharmacology.
Our chemistry team synthesises and delivers novel chemical substances: the stepping stones on the path to new drug development.
Our biotherapeutics team uses patented techniques to generate therapeutic antibodies and carries out affinity maturation and biophysical characterisation.
Many of our scientists come from pharmaceutical backgrounds and have experience of delivering successful drug discovery projects to industry standard.
Our expertise covers:
- Assay development
- Small molecule libraries
- Structural biology / in silico screening
- High-throughput screening
- Medicinal chemistry
- Antibody humanisation
- Antibody engineering
Four business development managers identify projects with development potential and seek commercial partners for projects at the appropriate time.